Theralink(R) Technologies to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16th

DENVER, CO / ACCESSWIRE / September 10, 2020 / OncBioMune d/b/a Theralink Technologies (OTC PINK:OBMP) (“Theralink” or the “Company”), a molecular profiling company specializing in patented, biomarker assay services that target multiple areas of oncology, announced today that Mick Ruxin, M.D., President and CEO of Theralink, will present at the H.C. Wainwright 22nd Annual Global Investment Conference to be held virtually on Wednesday, September 16, 2020.

Dr. Ruxin will present via live webcast at 12:30 p.m. ET. To attend, please register here: https://rb.gy/oifxe9

For more information about the H.C. Wainwright Conference, or to schedule a one-on-one meeting with Theralink’s management, please contact Theralink’s Investor Relations at Theralink@kcsa.com or H.C. Wainwright at meetings@hcwco.com.

About Theralink Technologies, Inc.
Theralink Technologies is a proteomics-based, molecular profiling company, located in Golden, Colorado that uniquely specializes in patented, phosphoprotein and protein biomarker assay services that target multiple areas of oncology. Theralink provides precision oncology data through its powerful Theralink® Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. We intend to improve cancer outcomes for patients, reveal therapeutic options for oncologists, and support biopharmaceutical drug development by using a beyond-genomics approach to molecular profiling that directly measures drug target levels and activity. For more information, please visit www.theralink.com.

Contact Information
Theralink Technologies, Inc.
KCSA Strategic Communications
Valter Pinto
Managing Director
212.896.1254
valter@kcsa.com

SOURCE: OncbioMune/Theralink

View source version on accesswire.com:
https://www.accesswire.com/605220/TheralinkR-Technologies-to-Present-at-the-HC-Wainwright-22nd-Annual-Global-Investment-Conference-on-September-16th

Staff

Recent Posts

SHOWCASING TOMORROW’S INNOVATORS: LG NOVA RETURNS TO CES 2025

LG NOVA Pushes Forward the Future of Collaboration and Innovation Across Healthtech, AI and Cleantech…

4 hours ago

AEON Biopharma, Inc. Announces Launch of Proposed Public Offering

IRVINE, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”)…

13 hours ago

Oculis Publishes Notification of Major Changes in Voting Rights

ZUG, Switzerland, Jan. 04, 2025 (GLOBE NEWSWIRE) -- Attached is a Notification of Major Changes…

13 hours ago

ARCPOINT CLOSES SALE OF OWNERSHIP STAKE IN NON-CORE ASSET

Greenville, South Carolina , Jan. 03, 2025 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the…

13 hours ago

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Carlsbad, CA, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade”, “Palisade…

13 hours ago

PharmaTher Announces Grant of Stock Options

TORONTO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB:…

13 hours ago